Tags

Type your tag names separated by a space and hit enter

A study on maize proteins as a potential new tablet excipient.
Eur J Pharm Biopharm. 2008 Jun; 69(2):718-26.EJ

Abstract

This investigation has examined the use of zein proteins from maize as the major component in oral controlled-release tablets, such formulations often being required to improve patient compliance. Tablets containing ground zein proteins, calcium hydrogen orthophosphate, polyvinyl pyrrolidone, theophylline and magnesium stearate were produced by wet granulation and compression on a single station tablet press and were compared to directly compressed tablets based on zein proteins, calcium hydrogen orthophosphate and theophylline. Non invasive techniques such as Fourier Transform infrared spectroscopy and Fourier Transform Raman spectroscopy were employed to investigate any changes in the secondary structure of zein proteins during tablet production. Random coils, alpha helices and beta sheets predominated and their relative content remained unaffected during grinding, wet granulation and compression, indicating that formulations based on zeins will be robust, i.e. insensitive to minor changes in the production conditions. Drug release from the tablets was studied using a standard pharmacopoeial dissolution test. Dissolution profiles in water, 0.1M HCl (pH=1) and phosphate buffer (pH=6.8) show that only a limited amount of theophylline was released after 4.5h, suggesting that zein proteins could act as a potential vehicle for oral controlled drug release. Analysis of the theophylline release profiles using the Peppas and Sahlin model reveals that diffusion and polymer relaxation occurred in acidic (pH=1) and buffered (pH=6.8) conditions for wet granulated tablets, whereas diffusion was predominant in directly compressed tablets. In conclusion, the present study has shown that zeins can be successfully used as a pharmaceutical excipient, and in particular as a matrix in monolithic controlled release tablets.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Georget DM
University of East Anglia, Norwich, UK. d.georget@uea.ac.uk <d.georget@uea.ac.uk>
Barker SA
No affiliation info available
Belton PS
No affiliation info available

MeSH

Chemistry, PharmaceuticalDelayed-Action PreparationsDrug CompoundingExcipientsKineticsMicroscopy, Electron, ScanningParticle SizePlant ProteinsSolubilitySpectroscopy, Fourier Transform InfraredSpectrum Analysis, RamanTabletsZea maysZein

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18294824

Citation

Georget, Dominique M R., et al. "A Study On Maize Proteins as a Potential New Tablet Excipient." European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, vol. 69, no. 2, 2008, pp. 718-26.
Georget DM, Barker SA, Belton PS. A study on maize proteins as a potential new tablet excipient. Eur J Pharm Biopharm. 2008;69(2):718-26.
Georget, D. M., Barker, S. A., & Belton, P. S. (2008). A study on maize proteins as a potential new tablet excipient. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, 69(2), 718-26. https://doi.org/10.1016/j.ejpb.2008.01.006
Georget DM, Barker SA, Belton PS. A Study On Maize Proteins as a Potential New Tablet Excipient. Eur J Pharm Biopharm. 2008;69(2):718-26. PubMed PMID: 18294824.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A study on maize proteins as a potential new tablet excipient. AU - Georget,Dominique M R, AU - Barker,Susan A, AU - Belton,Peter S, Y1 - 2008/01/18/ PY - 2007/11/07/received PY - 2008/01/08/revised PY - 2008/01/09/accepted PY - 2008/2/26/pubmed PY - 2008/8/30/medline PY - 2008/2/26/entrez SP - 718 EP - 26 JF - European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V JO - Eur J Pharm Biopharm VL - 69 IS - 2 N2 - This investigation has examined the use of zein proteins from maize as the major component in oral controlled-release tablets, such formulations often being required to improve patient compliance. Tablets containing ground zein proteins, calcium hydrogen orthophosphate, polyvinyl pyrrolidone, theophylline and magnesium stearate were produced by wet granulation and compression on a single station tablet press and were compared to directly compressed tablets based on zein proteins, calcium hydrogen orthophosphate and theophylline. Non invasive techniques such as Fourier Transform infrared spectroscopy and Fourier Transform Raman spectroscopy were employed to investigate any changes in the secondary structure of zein proteins during tablet production. Random coils, alpha helices and beta sheets predominated and their relative content remained unaffected during grinding, wet granulation and compression, indicating that formulations based on zeins will be robust, i.e. insensitive to minor changes in the production conditions. Drug release from the tablets was studied using a standard pharmacopoeial dissolution test. Dissolution profiles in water, 0.1M HCl (pH=1) and phosphate buffer (pH=6.8) show that only a limited amount of theophylline was released after 4.5h, suggesting that zein proteins could act as a potential vehicle for oral controlled drug release. Analysis of the theophylline release profiles using the Peppas and Sahlin model reveals that diffusion and polymer relaxation occurred in acidic (pH=1) and buffered (pH=6.8) conditions for wet granulated tablets, whereas diffusion was predominant in directly compressed tablets. In conclusion, the present study has shown that zeins can be successfully used as a pharmaceutical excipient, and in particular as a matrix in monolithic controlled release tablets. SN - 0939-6411 UR - https://www.unboundmedicine.com/medline/citation/18294824/A_study_on_maize_proteins_as_a_potential_new_tablet_excipient_ DB - PRIME DP - Unbound Medicine ER -